Absolute bioavailability and dose proportionality of BMS-181885, an antimigraine agent, following the administration of single intranasal doses to cynomolgus monkeys

Journal of Pharmaceutical Sciences

Volumn 87, Issue 9, 1998, Pages 1170-1172

  Srinivas, Nuggehally R ^a   Shyu, Wen Chyi ^a   Soong, Chi Wen ^a   Greene, Douglas ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; BMS 181885; SEROTONIN 1 RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METERED DOSE INHALER; MIGRAINE; MONKEY; NONHUMAN;

EID: 15444359798     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9802042     Document Type: Article

References (17)

1. Lance, J. W.; Anthony, M.; Hinterberger, H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967, 7, 93-102.
2. Toda, N.; Fujita, Y. Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine, and transmural electrical stimulation. Circ. Res. 1973, 33, 98-104.
3. Kimball, R. W.; Friedman, A. P.; Vallejo, E. Efect of serotonin in migraine patients. Neurology 1960, 10, 107-111.
4. Lance, J. W.; Anthony, M.; Gonski, A. G. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Arch. Neurology 1967, 16, 553-558.
5. Edwards, T. B. Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Clin. Ther. 1995, 17, 1032-1041.
6. Donnelly, A.; Bernstein, D. I.; Goldstein, S.; Grossman, J.; Schwartz, H. J.; Casale, T. B. Speed of onset of action of tilarin. Allergy 1996, 51, 14-19.
7. Bechgaard, E.; Gizurarson, S.; Hjortkjer, R. K. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. J. Pharm. Pharmacol. 1997, 49, 747-750.
8. Di-Costanzo, A.; Toriello, A.; Mannara, C.; Benvenuti, C.; Tedeschi, G. Intranasal versus neostigmine in myasthenia gravis: assessment by computer analysis of saccadic movements. Clin. Neuropharmacol. 1993, 16, 511-517.
9. Bertino, J. S., Jr. Intranasal mupirocin for outbreaks of methicillin-resistant staphylococcus aureus. Am. J. Health Syst. Pharm. 1997, 54, 2185-2191.
10. Humbert, H.; Cabiac, M. D.; Dubray, C.; Lavene, D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin. Pharmacol. Ther. 1996, 60, 265-275.
11. Moore, K. H.; Hussey, E. K.; Shaw, S.; Fuseau, E.; Duquesnoy, C.; Pakes, G. E. Safety, tolerability, and pharmacokinetics of Sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalgia 1997, 17, 541-550.
12. Gills, J. C.; Benfield, P.; Goa, K. L. Transnasal butorphanol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995, 50, 157-175.
13. Srinivas, N. R.; Shyu, W. C.; Upmalis, D.; Lee, J. S.; Barbhaiya, R. H. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. J. Clin. Pharmacol. 1995, 35, 432-437.
14. Srinivas, N. R.; Shah, V.; Schuster, A.; Whigan, D.; Shyu, W. C. High-performance liquid chromatographicc-electrochemical assay for the quantitation of BMS-181885 in monkey plasma. J. Chromatogr. B 1998, 705, 317-322.
15. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed.; Marcel Dekker: New York, 1982; p 409-417.
16. Riegelman, S.; Collier, P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokin. Biopharm. 1980, 8, 509-534.
17. SAS Institute Inc., SAS/STAT User's Guide, version 6, 4th ed., Vol 1 and 2, Cary, NC: SAS Institute Inc., 1989.